Trends in net survival from kidney cancer in six European Latin countries: results from the SUDCAN population-based study

Lucia Mangone, Nadine Bossard, Rafael Marcos-Gragera, Annamaria Pezzarossi, Francesca Roncaglia, Paolo Giorgi Rossi, GRELL EUROCARE-5 Working Group, Gemma Gatta, Milena Sant, Hade Amash

Research output: Contribution to journalArticle

Abstract

Kidney cancer is a frequent malignant disease. To date, there is no evidence on the effectiveness of early detection and, in most cases, surgery represents the only standard treatment. So far, there is no standardized therapy for localized and locally advanced renal tumors; however, the recent introduction of target therapy has significantly improved the prognosis of metastatic disease. Therefore, survival differences in Europe are deemed to involve differences in diagnostic and therapeutic approaches. The aim of the SUDCAN collaborative study was to compare the net survival from kidney cancer between six European Latin countries (Belgium, France, Italy, Portugal, Spain, and Switzerland) and provide trends in net survival and dynamics of excess mortality rates up to 5 years after diagnosis. The data were extracted from the EUROCARE-5 database. First, net survival was studied over the 2000-2004 period using the Pohar-Perme estimator. For trend analysis, the study period was specific to each country. The results are reported from 1992 to 2004 in France, Italy, Spain, and Switzerland, and from 2000 to 2004 in Belgium and Portugal. These analyses were carried out using a flexible excess rate modeling strategy. In 2000-2004, the 5-year net survival ranged between 59% (Spain) and 67% (France and Italy) in men and between 60% (Spain) and 73% (Portugal) in women. There was an increase in the age-standardized net survival between 1992 and 2004 at 1 year, as well as at 5 years, in all age groups and countries. Irrespective of the year of diagnosis, the excess mortality rate decreased with time elapsed since diagnosis. There are some differences in survival from kidney cancer between European Latin countries, but a considerable improvement was observed in most countries.

Original languageEnglish
Pages (from-to)S121-S127
JournalEuropean Journal of Cancer Prevention
Volume26 Trends in cancer net survival in six European Latin Countries: the SUDCAN study
DOIs
Publication statusPublished - Jan 2017

Fingerprint

Kidney Neoplasms
Survival
Spain
Portugal
Population
Italy
France
Mortality
Belgium
Switzerland
Therapeutics
Age Groups
Databases
Kidney
Neoplasms

Keywords

  • Journal Article

Cite this

Mangone, L., Bossard, N., Marcos-Gragera, R., Pezzarossi, A., Roncaglia, F., Giorgi Rossi, P., ... Amash, H. (2017). Trends in net survival from kidney cancer in six European Latin countries: results from the SUDCAN population-based study. European Journal of Cancer Prevention, 26 Trends in cancer net survival in six European Latin Countries: the SUDCAN study, S121-S127. https://doi.org/10.1097/CEJ.0000000000000297

Trends in net survival from kidney cancer in six European Latin countries : results from the SUDCAN population-based study. / Mangone, Lucia; Bossard, Nadine; Marcos-Gragera, Rafael; Pezzarossi, Annamaria; Roncaglia, Francesca; Giorgi Rossi, Paolo; GRELL EUROCARE-5 Working Group ; Gatta, Gemma; Sant, Milena; Amash, Hade.

In: European Journal of Cancer Prevention, Vol. 26 Trends in cancer net survival in six European Latin Countries: the SUDCAN study, 01.2017, p. S121-S127.

Research output: Contribution to journalArticle

Mangone, L, Bossard, N, Marcos-Gragera, R, Pezzarossi, A, Roncaglia, F, Giorgi Rossi, P, GRELL EUROCARE-5 Working Group, Gatta, G, Sant, M & Amash, H 2017, 'Trends in net survival from kidney cancer in six European Latin countries: results from the SUDCAN population-based study', European Journal of Cancer Prevention, vol. 26 Trends in cancer net survival in six European Latin Countries: the SUDCAN study, pp. S121-S127. https://doi.org/10.1097/CEJ.0000000000000297
Mangone L, Bossard N, Marcos-Gragera R, Pezzarossi A, Roncaglia F, Giorgi Rossi P et al. Trends in net survival from kidney cancer in six European Latin countries: results from the SUDCAN population-based study. European Journal of Cancer Prevention. 2017 Jan;26 Trends in cancer net survival in six European Latin Countries: the SUDCAN study:S121-S127. https://doi.org/10.1097/CEJ.0000000000000297
Mangone, Lucia ; Bossard, Nadine ; Marcos-Gragera, Rafael ; Pezzarossi, Annamaria ; Roncaglia, Francesca ; Giorgi Rossi, Paolo ; GRELL EUROCARE-5 Working Group ; Gatta, Gemma ; Sant, Milena ; Amash, Hade. / Trends in net survival from kidney cancer in six European Latin countries : results from the SUDCAN population-based study. In: European Journal of Cancer Prevention. 2017 ; Vol. 26 Trends in cancer net survival in six European Latin Countries: the SUDCAN study. pp. S121-S127.
@article{9c51289483f74aecafc51e4622db8f5b,
title = "Trends in net survival from kidney cancer in six European Latin countries: results from the SUDCAN population-based study",
abstract = "Kidney cancer is a frequent malignant disease. To date, there is no evidence on the effectiveness of early detection and, in most cases, surgery represents the only standard treatment. So far, there is no standardized therapy for localized and locally advanced renal tumors; however, the recent introduction of target therapy has significantly improved the prognosis of metastatic disease. Therefore, survival differences in Europe are deemed to involve differences in diagnostic and therapeutic approaches. The aim of the SUDCAN collaborative study was to compare the net survival from kidney cancer between six European Latin countries (Belgium, France, Italy, Portugal, Spain, and Switzerland) and provide trends in net survival and dynamics of excess mortality rates up to 5 years after diagnosis. The data were extracted from the EUROCARE-5 database. First, net survival was studied over the 2000-2004 period using the Pohar-Perme estimator. For trend analysis, the study period was specific to each country. The results are reported from 1992 to 2004 in France, Italy, Spain, and Switzerland, and from 2000 to 2004 in Belgium and Portugal. These analyses were carried out using a flexible excess rate modeling strategy. In 2000-2004, the 5-year net survival ranged between 59{\%} (Spain) and 67{\%} (France and Italy) in men and between 60{\%} (Spain) and 73{\%} (Portugal) in women. There was an increase in the age-standardized net survival between 1992 and 2004 at 1 year, as well as at 5 years, in all age groups and countries. Irrespective of the year of diagnosis, the excess mortality rate decreased with time elapsed since diagnosis. There are some differences in survival from kidney cancer between European Latin countries, but a considerable improvement was observed in most countries.",
keywords = "Journal Article",
author = "Lucia Mangone and Nadine Bossard and Rafael Marcos-Gragera and Annamaria Pezzarossi and Francesca Roncaglia and {Giorgi Rossi}, Paolo and {GRELL EUROCARE-5 Working Group} and Gemma Gatta and Milena Sant and Hade Amash",
year = "2017",
month = "1",
doi = "10.1097/CEJ.0000000000000297",
language = "English",
volume = "26 Trends in cancer net survival in six European Latin Countries: the SUDCAN study",
pages = "S121--S127",
journal = "European Journal of Cancer Prevention",
issn = "0959-8278",
publisher = "Lippincott Williams and Wilkins",

}

TY - JOUR

T1 - Trends in net survival from kidney cancer in six European Latin countries

T2 - results from the SUDCAN population-based study

AU - Mangone, Lucia

AU - Bossard, Nadine

AU - Marcos-Gragera, Rafael

AU - Pezzarossi, Annamaria

AU - Roncaglia, Francesca

AU - Giorgi Rossi, Paolo

AU - GRELL EUROCARE-5 Working Group

AU - Gatta, Gemma

AU - Sant, Milena

AU - Amash, Hade

PY - 2017/1

Y1 - 2017/1

N2 - Kidney cancer is a frequent malignant disease. To date, there is no evidence on the effectiveness of early detection and, in most cases, surgery represents the only standard treatment. So far, there is no standardized therapy for localized and locally advanced renal tumors; however, the recent introduction of target therapy has significantly improved the prognosis of metastatic disease. Therefore, survival differences in Europe are deemed to involve differences in diagnostic and therapeutic approaches. The aim of the SUDCAN collaborative study was to compare the net survival from kidney cancer between six European Latin countries (Belgium, France, Italy, Portugal, Spain, and Switzerland) and provide trends in net survival and dynamics of excess mortality rates up to 5 years after diagnosis. The data were extracted from the EUROCARE-5 database. First, net survival was studied over the 2000-2004 period using the Pohar-Perme estimator. For trend analysis, the study period was specific to each country. The results are reported from 1992 to 2004 in France, Italy, Spain, and Switzerland, and from 2000 to 2004 in Belgium and Portugal. These analyses were carried out using a flexible excess rate modeling strategy. In 2000-2004, the 5-year net survival ranged between 59% (Spain) and 67% (France and Italy) in men and between 60% (Spain) and 73% (Portugal) in women. There was an increase in the age-standardized net survival between 1992 and 2004 at 1 year, as well as at 5 years, in all age groups and countries. Irrespective of the year of diagnosis, the excess mortality rate decreased with time elapsed since diagnosis. There are some differences in survival from kidney cancer between European Latin countries, but a considerable improvement was observed in most countries.

AB - Kidney cancer is a frequent malignant disease. To date, there is no evidence on the effectiveness of early detection and, in most cases, surgery represents the only standard treatment. So far, there is no standardized therapy for localized and locally advanced renal tumors; however, the recent introduction of target therapy has significantly improved the prognosis of metastatic disease. Therefore, survival differences in Europe are deemed to involve differences in diagnostic and therapeutic approaches. The aim of the SUDCAN collaborative study was to compare the net survival from kidney cancer between six European Latin countries (Belgium, France, Italy, Portugal, Spain, and Switzerland) and provide trends in net survival and dynamics of excess mortality rates up to 5 years after diagnosis. The data were extracted from the EUROCARE-5 database. First, net survival was studied over the 2000-2004 period using the Pohar-Perme estimator. For trend analysis, the study period was specific to each country. The results are reported from 1992 to 2004 in France, Italy, Spain, and Switzerland, and from 2000 to 2004 in Belgium and Portugal. These analyses were carried out using a flexible excess rate modeling strategy. In 2000-2004, the 5-year net survival ranged between 59% (Spain) and 67% (France and Italy) in men and between 60% (Spain) and 73% (Portugal) in women. There was an increase in the age-standardized net survival between 1992 and 2004 at 1 year, as well as at 5 years, in all age groups and countries. Irrespective of the year of diagnosis, the excess mortality rate decreased with time elapsed since diagnosis. There are some differences in survival from kidney cancer between European Latin countries, but a considerable improvement was observed in most countries.

KW - Journal Article

U2 - 10.1097/CEJ.0000000000000297

DO - 10.1097/CEJ.0000000000000297

M3 - Article

C2 - 28005615

VL - 26 Trends in cancer net survival in six European Latin Countries: the SUDCAN study

SP - S121-S127

JO - European Journal of Cancer Prevention

JF - European Journal of Cancer Prevention

SN - 0959-8278

ER -